SG11201703403TA - Anti-tim-3 antibodies - Google Patents
Anti-tim-3 antibodiesInfo
- Publication number
- SG11201703403TA SG11201703403TA SG11201703403TA SG11201703403TA SG11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA
- Authority
- SG
- Singapore
- Prior art keywords
- tim
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201419089A GB201419089D0 (en) | 2014-10-27 | 2014-10-27 | Anti-TIM-3 antibodies |
GB201419092A GB201419092D0 (en) | 2014-10-27 | 2014-10-27 | Anti-TIM-3 antibodies |
PCT/SG2015/050415 WO2016068803A1 (en) | 2014-10-27 | 2015-10-27 | Anti-tim-3 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703403TA true SG11201703403TA (en) | 2017-05-30 |
Family
ID=55857945
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201803042PA SG10201803042PA (en) | 2014-10-27 | 2015-10-27 | Anti-tim-3 antibodies |
SG11201703403TA SG11201703403TA (en) | 2014-10-27 | 2015-10-27 | Anti-tim-3 antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201803042PA SG10201803042PA (en) | 2014-10-27 | 2015-10-27 | Anti-tim-3 antibodies |
Country Status (9)
Country | Link |
---|---|
US (2) | US10259874B2 (en) |
EP (1) | EP3212231B1 (en) |
JP (1) | JP6709215B2 (en) |
KR (1) | KR20170075778A (en) |
CN (2) | CN107405397B (en) |
AU (1) | AU2015340056A1 (en) |
CA (1) | CA2965960A1 (en) |
SG (2) | SG10201803042PA (en) |
WO (1) | WO2016068803A1 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201419094D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
CN107405397B (en) | 2014-10-27 | 2020-08-25 | 新加坡科技研究局 | anti-TIM-3 antibodies |
CA2978892A1 (en) * | 2015-03-06 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
US11014983B2 (en) | 2015-08-20 | 2021-05-25 | Sutro Biopharma, Inc. | Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies |
AU2017271588B2 (en) * | 2016-05-27 | 2022-01-20 | Agenus Inc. | Anti-TIM-3 antibodies and methods of use thereof |
IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Anti-pd-l1 antibodies |
EP3484920A2 (en) | 2016-07-14 | 2019-05-22 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
JOP20190013A1 (en) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | Anti-tim-3 antibodies |
SG10201912199XA (en) | 2016-08-26 | 2020-02-27 | Beigene Ltd | Anti-tim-3 antibodies and use thereof |
WO2018075954A2 (en) * | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
JOP20190133A1 (en) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies |
CN108264557B (en) * | 2016-12-30 | 2021-08-24 | 惠和生物技术(上海)有限公司 | Bifunctional molecule combining CD3 and T cell negative co-stimulatory molecule and application thereof |
US11046764B2 (en) | 2017-01-03 | 2021-06-29 | Trellis Bioscience, Llc | Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3 |
EP3574019A4 (en) | 2017-01-26 | 2021-03-03 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
WO2019023410A1 (en) | 2017-07-28 | 2019-01-31 | Phanes Therapeutics, Inc. | Anti-tim-3 antibodies and uses thereof |
JP2020531854A (en) | 2017-08-28 | 2020-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | TIM-3 antagonists for the treatment and diagnosis of cancer |
WO2019092181A1 (en) | 2017-11-10 | 2019-05-16 | Agency For Science, Technology And Research | Il2rbeta/common gamma chain antibodies |
WO2019140229A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
KR20200109339A (en) | 2018-01-16 | 2020-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | How to treat cancer using antibodies to TIM3 |
EP3758751A4 (en) * | 2018-02-28 | 2021-11-17 | Wuxi Biologics Ireland Limited. | Monoclonal antibody against human lag-3, method for preparing same, and use thereof |
CN110272489B (en) * | 2018-03-15 | 2023-08-22 | 上海健信生物医药科技有限公司 | Fully humanized antibody molecule, antigen binding fragment and medical application thereof aiming at TIM-3 |
CN110305216B (en) * | 2018-03-20 | 2022-09-02 | 无锡智康弘义生物科技有限公司 | Novel anti-TIM-3 antibodies |
CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
CN116789827A (en) | 2018-04-12 | 2023-09-22 | 南京维立志博生物科技有限公司 | Methods of treating diseases using TIM-3 binding antibodies |
CA3098096A1 (en) * | 2018-04-24 | 2019-10-31 | Ampsource Biopharma Shanghai Inc. | Antibody against tim-3 and application thereof |
JP2021528393A (en) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Increased immune activity by regulation of posterior cell signaling factors |
CA3104470A1 (en) * | 2018-06-19 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Anti-factor xii/xiia antibodies and uses thereof |
CA3104868A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
EP3876988A4 (en) * | 2018-11-09 | 2022-11-09 | Beth Israel Deaconess Medical Center | Cdcp1-targeted therapies |
WO2020094836A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
MA55805A (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | METHODS OF MODULATING IMMUNE ACTIVITY |
EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
KR20220016155A (en) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy |
US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
CN110498855A (en) * | 2019-07-25 | 2019-11-26 | 钟小泉 | A kind of TIM-3 antibody and application thereof |
CN110922478B (en) * | 2019-12-07 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Fully human monoclonal antibody against chikungunya fever and application thereof |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
CN113150150B (en) * | 2020-02-24 | 2023-08-11 | 苏州恒康生命科学有限公司 | TIM3 binding molecules and uses thereof |
KR102536302B1 (en) * | 2020-02-25 | 2023-05-26 | 국립암센터 | Monoclonal antibody specifically binding to TIM-3 and uses thereof |
CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
CN112094348B (en) * | 2020-09-22 | 2021-11-30 | 首都医科大学附属北京胸科医院 | Anti-human Tim3 antibody or functional fragment thereof and application thereof |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
JP2024501029A (en) | 2020-12-28 | 2024-01-10 | ブリストル-マイヤーズ スクイブ カンパニー | Subcutaneous administration of PD1/PD-L1 antibodies |
EP4267105A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
CA3208935A1 (en) * | 2021-01-22 | 2022-07-28 | Elpis Biopharmaceuticals | Bispecific chimeric antigen receptors binding to cd19 and cd22 |
EP4083065A1 (en) * | 2021-01-28 | 2022-11-02 | NantBio, Inc. | Anti-tim3 monoclonal antibodies and chimeric antigen receptors |
WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
JP2024514530A (en) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibodies against truncated CDCP1 and uses thereof |
EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
CN114181311B (en) * | 2021-12-20 | 2023-06-20 | 华东师范大学 | Fully human anti-DLL 3 scFv and application thereof in CART cell therapy |
WO2023168195A2 (en) * | 2022-03-04 | 2023-09-07 | The Scripps Research Institute | Human broadly neutralizing antibodies against betacoronaviruses |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
ES2192426B1 (en) | 2000-05-11 | 2005-02-16 | Universidad De Vigo | SM50 / 20 HUMAN MONOCLONAL ANTIBODY RECOGNIZING HUMAN LEUKOCYTES, AND THEIR USE IN THERAPY. |
DE60333228D1 (en) | 2002-12-02 | 2010-08-12 | Amgen Fremont Inc | AGAINST THE TUMOR NEKROSE FACTOR TARGETED ANTIBODIES AND THEIR USES |
EP3000886A1 (en) | 2003-03-19 | 2016-03-30 | Amgen Fremont Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
BRPI0414924A (en) * | 2003-10-03 | 2006-11-07 | Brigham & Womens Hospital | tim-3 ligands and their methods |
EP2100618B1 (en) | 2005-06-17 | 2014-02-12 | ImClone LLC | An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer |
AU2006315580A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen |
EP2252319A2 (en) * | 2008-01-29 | 2010-11-24 | The Brigham and Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
CA2732003A1 (en) | 2008-07-31 | 2010-02-04 | James D. Marks | Antibodies that neutralize botulinum neurotoxins |
CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
JP2013523184A (en) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | Human FGF receptor and β-KLOTHO binding protein |
CA2814155C (en) * | 2010-06-11 | 2019-10-22 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
CN102392038B (en) | 2011-11-01 | 2013-04-17 | 浙江大学 | Expression vector for deleting exogenous genes in polished rice of transgenic rice and application thereof |
CN102492038B (en) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof |
EP3698809A1 (en) | 2012-07-31 | 2020-08-26 | The Brigham & Women's Hospital, Inc. | Modulation of the immune response using agents binding tim-3 and ceacam-1 |
CN104379169A (en) * | 2012-08-14 | 2015-02-25 | Ibc药品公司 | T-cell redirecting bispecific antibodies for treatment of disease |
CN103665164A (en) * | 2012-10-24 | 2014-03-26 | 中国人民解放军军事医学科学院基础医学研究所 | ELISA (enzyme-linked immunosorbent assay) kit for detecting Tim-3 |
WO2014070874A1 (en) | 2012-10-31 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways |
US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
JP2014162739A (en) * | 2013-02-22 | 2014-09-08 | National Institute Of Biomedical Innovation | Bispecific antibody and pharmaceutical composition |
EP3089994B1 (en) * | 2013-12-30 | 2022-05-04 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
CN103936853B (en) * | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | A kind of detection TIM-3 test kit and using method thereof |
JOP20200096A1 (en) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
CN107405397B (en) | 2014-10-27 | 2020-08-25 | 新加坡科技研究局 | anti-TIM-3 antibodies |
GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
CN104592388B (en) * | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | A kind of antigen-binding portion thereof of the monoclonal antibody of anti-human Tim 3 |
-
2015
- 2015-10-27 CN CN201580071169.9A patent/CN107405397B/en active Active
- 2015-10-27 EP EP15855010.3A patent/EP3212231B1/en active Active
- 2015-10-27 SG SG10201803042PA patent/SG10201803042PA/en unknown
- 2015-10-27 AU AU2015340056A patent/AU2015340056A1/en not_active Abandoned
- 2015-10-27 KR KR1020177014444A patent/KR20170075778A/en unknown
- 2015-10-27 JP JP2017522640A patent/JP6709215B2/en active Active
- 2015-10-27 US US15/521,685 patent/US10259874B2/en active Active
- 2015-10-27 SG SG11201703403TA patent/SG11201703403TA/en unknown
- 2015-10-27 CA CA2965960A patent/CA2965960A1/en not_active Abandoned
- 2015-10-27 WO PCT/SG2015/050415 patent/WO2016068803A1/en active Application Filing
- 2015-10-27 CN CN201910641759.0A patent/CN110294807B/en active Active
-
2019
- 2019-03-06 US US16/294,474 patent/US11142574B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG10201803042PA (en) | 2018-06-28 |
CN110294807B (en) | 2023-05-12 |
KR20170075778A (en) | 2017-07-03 |
CN107405397B (en) | 2020-08-25 |
US10259874B2 (en) | 2019-04-16 |
JP6709215B2 (en) | 2020-06-10 |
JP2017536111A (en) | 2017-12-07 |
US20190185564A1 (en) | 2019-06-20 |
CA2965960A1 (en) | 2016-05-06 |
EP3212231B1 (en) | 2021-04-28 |
CN110294807A (en) | 2019-10-01 |
CN107405397A (en) | 2017-11-28 |
EP3212231A1 (en) | 2017-09-06 |
US20170240633A1 (en) | 2017-08-24 |
EP3212231A4 (en) | 2018-03-28 |
WO2016068803A1 (en) | 2016-05-06 |
AU2015340056A1 (en) | 2017-05-25 |
US11142574B2 (en) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250583A0 (en) | Anti-tigit antibodies | |
IL252004A0 (en) | Domain-exchanged antibody | |
SG11201703403TA (en) | Anti-tim-3 antibodies | |
SG11201703346PA (en) | Anti-tim-3 antibodies | |
IL252422A0 (en) | Effector-deficient anti-cd32a antibodies | |
IL291164A (en) | Anti-nme antibody | |
IL250374B (en) | Anti-ceramide antibodies | |
IL246603A0 (en) | Novel anti-netrin-1 antibody | |
GB201410520D0 (en) | Antibody | |
SG11201700922YA (en) | Anti-orai1 antibody | |
PL3628731T3 (en) | Novel anti-presepsin antibody | |
IL247988A0 (en) | Antibodies against hpa-1a | |
GB201419092D0 (en) | Anti-TIM-3 antibodies | |
GB201419089D0 (en) | Anti-TIM-3 antibodies | |
GB201417614D0 (en) | Antibodies | |
GB201414270D0 (en) | Antibodies | |
GB201418776D0 (en) | Antibody | |
GB201405775D0 (en) | Antibodies | |
GB201401200D0 (en) | Antibodies | |
GB201413745D0 (en) | Antibody | |
GB201411319D0 (en) | Antibody | |
GB201407535D0 (en) | Antibody Drug - Conjugates |